Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | NAT1 | P18440 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13923609 | 0.76 | MEN1 (0.37) | HTR2AOPRM1OPRL1CA2MEN1 | |
| SCHEMBL15657806 | 0.63 | OPRM1 (0.39) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL11703346 | 0.61 | NPY5R (0.39) | HTR2AOPRM1MEN1CYP1A2POLB | |
| SCHEMBL7102637 | 0.60 | KMT2A (0.47) | HTR2ACA2NAT1EPHX1MEN1 | |
| SCHEMBL4782402 | 0.60 | TDP1 (0.35) | HTR2AOPRM1MEN1CYP1A2POLB | |
| SCHEMBL10565247 | 0.60 | — | — | |
| SCHEMBL11596104 | 0.59 | GSK3A (0.36) | OPRM1OPRL1OPRK1CA2NAT1 | |
| SCHEMBL25366882 | 0.59 | MAPT (0.36) | HTR2AOPRM1OPRL1OPRK1MEN1 | |
| SCHEMBL1637914 | 0.58 | HTR2A (0.44) | HTR2AOPRM1OPRL1OPRK1 | |
| SCHEMBL1668502 | 0.58 | OPRM1 (0.48) | HTR2AOPRM1OPRL1OPRK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488818-B2 | Method for producing 1,4-diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-7488818-B2 | Method for producing 1,4-diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| EP-1756049-B1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-31 | — | — | EP | disclosed |
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | CYP46A1, CYP51A1, APOB | HTR2A 2950/4885OPRM1 4661/4885OPRL1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.